Hikma Pharmaceuticals: latest news - GoINPHARMA
Wednesday, 16 January 2019 - 18:05

Hikma Pharmaceuticals

Vectura targeted by AstraZeneca and Novartis (GBP700m)

The Daily Telegraph has reported today that UK-based Vectura Group is targeted by AstraZeneca. According to rumors circulating yesterday, instead, Novartis–a partner of Vectura’s–is planning to acquire it completely. Vectura’s shares have lost over 21% of their value since January…

Hikma lowers 2017 guidance and shares fall >5%

Hikma Pharmaceuticals today announced it has lowered its current year guidance, which has immediately resulted in a 5% capitalization loss. The news was announced a week after that US FDA rejected – temporarily – to approve the generic of GSK’s…

GSK celebrates non-approval of Hikma-developed generic Advair

GlaxoSmithKline scored another victory as FDA this week rejected to approve the generic of blockbuster Advair Diskus, developed by generic manufacturer Hikma. Britain-based Hikma Pharmaceuticals is seeking the same multibillion-pound sales that the asthma drug (fluticasone propionate and salmeterol) developed…

Hikma tests the market looking for takeover candidates

Hikma Pharmaceuticals CEO Said Darwazah said to The Daily Telegraph that his group is testing the market, looking for takeover candidates in North America, Europe and the Middle East. Hikma yesterday reported its 2016 financial results, which far exceeded analysts’…

Hikma dominates trading

Yesterday’s trading leader was Hikma Pharmaceuticals, a drugmaker focusing on producing and marketing generics. The group had previously provided rather gloomy guidance for 2016, yet its results have contradicted them. Indeed, Hikma reported a revenue of approximately $1.95bn, meeting expectations…